Lipids: HDL cholesterol is not HDL-don't judge the book by its cover

Nature Reviews Cardiology

Volumn 9, Issue 10, 2012, Pages 557-558

  Arsenault, Benoit J ^a   Després, Jean Pierre ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHARMACOLOGICAL BIOMARKER;

CARDIOVASCULAR RISK; DISEASE MARKER; GENETIC EPIDEMIOLOGY; GENETIC VARIABILITY; HUMAN; LIFESTYLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFECT; HYPERTRIGLYCERIDEMIA; METABOLISM; PATHOLOGY; UNITED STATES;

BIOMARKERS, PHARMACOLOGICAL; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; HYPERTRIGLYCERIDEMIA; RISK REDUCTION BEHAVIOR; UNITED STATES;

EID: 84866735892     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.127     Document Type: Review

References (10)

1. Mackey, R. H. et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 60, 508-516 (2012).
2. Otvos, J. D., Jeyarajah, E. J. & Bennett, D. W. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin. Chem. 37, 377-386 (1991).
3. El Harchaoui, K. et al. High-density lipoprotein particle size and concentration and coronary risk. Ann. Intern. Med. 150, 84-93 (2009).
4. Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127-135 (2011).
5. Patel, P. J., Khera, A. V., Jafri, K., Wilensky, R. L. & Rader, D. J. The antioxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J. Am. Coll. Cardiol. 58, 2068-2075 (2011).
6. Roche. Media release. Roche provides update on phase III study of dalcetrapib [online], http://www.roche.com/media/media-releases/med-cor-2012-05- 07.htm (2012).
7. Ballantyne, C. M. et al. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am. Heart J. 163, 515-521, 521.e1-e3 (2012).
8. Otvos, J. D. et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113, 1556-1563 (2006).
9. Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572-580 (2012).
10. Kaess, B. M. et al. Large-scale candidate gene analysis of HDL particle features. PLoS ONE 6, e14529 (2011).